Ke-Jing Tang

1 article listing Ke-Jing Tang in Nature Communications, indexed by Paperzzz from Crossref and OSF.

1. Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) Nature Communications